

An Coosemans

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5899374/publications.pdf>

Version: 2024-02-01

61
papers

2,308
citations

279798

23
h-index

233421

45
g-index

63
all docs

63
docs citations

63
times ranked

3489
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical management of uterine sarcomas. <i>Lancet Oncology</i> , The, 2009, 10, 1188-1198.	10.7	374
2	Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. <i>Frontiers in Immunology</i> , 2015, 6, 588.	4.8	317
3	Trial watch: dendritic cell vaccination for cancer immunotherapy. <i>Oncolimmunology</i> , 2019, 8, 1638212.	4.6	125
4	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2021, 7, 150.	5.2	112
5	Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study. <i>Lancet Oncology</i> , The, 2019, 20, 448-458.	10.7	110
6	Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal Masses. <i>Clinical Cancer Research</i> , 2017, 23, 2223-2231.	7.0	80
7	Screening for uterine tumours. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2012, 26, 257-266.	2.8	72
8	High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification. <i>Genome Medicine</i> , 2021, 13, 111.	8.2	70
9	Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 1273.	4.8	65
10	Validation of models to diagnose ovarian cancer in patients managed surgically or conservatively: multicentre cohort study. <i>BMJ</i> , The, 2020, 370, m2614.	6.0	54
11	Trial watch: Dendritic cell (DC)-based immunotherapy for cancer. <i>Oncolimmunology</i> , 2022, 11, .	4.6	54
12	Upregulation of Wilms' tumour gene 1 (WT1) in uterine sarcomas. <i>European Journal of Cancer</i> , 2007, 43, 1630-1637.	2.8	44
13	Age-related differences in the sonographic characteristics of endometriomas. <i>Human Reproduction</i> , 2016, 31, 1723-1731.	0.9	43
14	Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients. <i>Gynecologic Oncology</i> , 2018, 150, 31-37.	1.4	42
15	Wilms' Tumor Gene 1 (WT1)-loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial. <i>Anticancer Research</i> , 2013, 33, 5495-500.	1.1	37
16	Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma. <i>Anticancer Research</i> , 2013, 33, 3855-9.	1.1	36
17	Gemcitabine Recruits M2-Type Tumor-Associated Macrophages into the Stroma of Pancreatic Cancer. <i>Translational Oncology</i> , 2020, 13, 100743.	3.7	34
18	Genome-Wide Association Study Identifies a Possible Susceptibility Locus for Endometrial Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 980-987.	2.5	32

#	ARTICLE	IF	CITATIONS
19	Immunosuppressive parameters in serum of ovarian cancer patients change during the disease course. <i>Oncolmmunology</i> , 2016, 5, e1111505.	4.6	31
20	Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomasâ€”an ENITEC Group Initiative. <i>Clinical Cancer Research</i> , 2017, 23, 1274-1285.	7.0	30
21	Immunological configuration of ovarian carcinoma: features and impact on disease outcome. , 2021, 9, e002873.		30
22	Simultaneous in vivo PET/MRI using fluorine-18 labeled Fe ₃ O ₄ @Al(OH) ₃ nanoparticles: comparison of nanoparticle and nanoparticle-labeled stem cell distribution. <i>EJNMMI Research</i> , 2020, 10, 73.	2.5	28
23	Wilms' tumor gene 1 (WT1) in endometrial carcinoma. <i>Gynecologic Oncology</i> , 2008, 111, 502-508.	1.4	27
24	An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 3053-3065.	7.0	26
25	Combining conventional therapy with immunotherapy: AÂrisky business?. <i>European Journal of Cancer</i> , 2019, 113, 41-44.	2.8	25
26	Wilms Tumor Gene 1(WT1) is a Prognostic Marker in High-Grade Uterine Sarcoma. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 302-308.	2.5	24
27	Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer. , 2021, 9, e003609.		24
28	Polymorphisms in Inflammation Pathway Genes and Endometrial Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 216-223.	2.5	22
29	Opposite Macrophage Polarization in Different Subsets of Ovarian Cancer: Observation from a Pilot Study. <i>Cells</i> , 2020, 9, 305.	4.1	22
30	Clinical Outcome of ET-743 (Trabectedin; Yondelis) in High-Grade Uterine Sarcomas: Report on Five Patients and a Review of the Literature. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 245-248.	2.5	20
31	Ovarian cancer in children and adolescents: A rare disease that needs more attention. <i>Maturitas</i> , 2016, 88, 3-8.	2.4	19
32	Immunocompetent Mouse Models in the Search for Effective Immunotherapy in Glioblastoma. <i>Cancers</i> , 2021, 13, 19.	3.7	18
33	The dark side of ID8-Luc2: pitfalls for luciferase tagged murine models for ovarian cancer. , 2015, 3, 57.		17
34	Myeloid-derived suppressor cells at diagnosis may discriminate between benign and malignant ovarian tumors. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1381-1388.	2.5	17
35	Radiotherapy, Temozolomide, and Antiprogrammed Cell Death Protein 1 Treatments Modulate the Immune Microenvironment in Experimental High-Grade Glioma. <i>Neurosurgery</i> , 2021, 88, E205-E215.	1.1	17
36	Liquid Biopsy in Glioblastoma. <i>Cancers</i> , 2022, 14, 3394.	3.7	17

#	ARTICLE	IF	CITATIONS
37	Ovarian cancer and the immune system. <i>Gynecologic Oncology Reports</i> , 2017, 19, 57-58.	0.6	16
38	Circulating Protein Biomarkers to Differentiate Uterine Sarcomas from Leiomyomas. <i>Anticancer Research</i> , 2019, 39, 3981-3989.	1.1	14
39	The Use of Toll-like Receptor 4 Agonist to Reshape the Immune Signature in Ovarian Cancer. <i>Anticancer Research</i> , 2016, 36, 5781-5792.	1.1	14
40	Increased Immunosuppression Is Related to Increased Amounts of Ascites and Inferior Prognosis in Ovarian Cancer. <i>Anticancer Research</i> , 2019, 39, 5953-5962.	1.1	13
41	CT-2A neurospheres-derived high-grade glioma in mice: a new model to address tumor stem cells and immunosuppression. <i>Biology Open</i> , 2019, 8, .	1.2	12
42	Type of chemotherapy has substantial effects on the immune system in ovarian cancer. <i>Translational Oncology</i> , 2021, 14, 101076.	3.7	11
43	In Vitro Generation of Murine Dendritic Cells for Cancer Immunotherapy: An Optimized Protocol. <i>Anticancer Research</i> , 2016, 36, 5793-5802.	1.1	11
44	Dendritic cell-based immunotherapy in ovarian cancer. <i>OncolImmunology</i> , 2013, 2, e27059.	4.6	10
45	Radiation dose-escalation and dose-fractionation modulate the immune microenvironment, cancer stem cells and vasculature in experimental high-grade gliomas. <i>Journal of Neurosurgical Sciences</i> , 2020, , .	0.6	10
46	Morcellation and risk of malignancy in presumed ovarian fibromas/fibrothecomas. <i>Lancet Oncology</i> , The, 2016, 17, 273-274.	10.7	9
47	Neo-Adjuvant Chemotherapy Reduces, and Surgery Increases Immunosuppression in First-Line Treatment for Ovarian Cancer. <i>Cancers</i> , 2021, 13, 5899.	3.7	9
48	Wilms' tumor gene 1 (WT1) overexpression in neurons in deep endometriosis: a pilot study. <i>Fertility and Sterility</i> , 2009, 91, 1441-1444.	1.0	8
49	Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors. <i>Gynecologic Oncology</i> , 2020, 159, 811-819.	1.4	8
50	Dendritic cell immunotherapy in uterine cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1822-1827.	3.3	6
51	A first-in-class, non-invasive, immunodynamic biomarker approach for precision immuno-oncology. <i>OncolImmunology</i> , 2022, 11, 2024692.	4.6	6
52	Pan-Cancer Detection and Typing by Mining Patterns in Large Genome-Wide Cell-Free DNA Sequencing Datasets. <i>Clinical Chemistry</i> , 2022, 68, 1164-1176.	3.2	6
53	mRNA Electroporation of Dendritic Cells with WT1, Survivin, and TriMix (a Mixture of caTLR4, CD40L,) Tj ETQq1 1 0,784314 rgBT /Over	0.9	5
54	CryptoCEST: A promising tool for spatially resolved identification of fungal brain lesions and their differentiation from brain tumors with MRI. <i>NeuroImage: Clinical</i> , 2021, 31, 102737.	2.7	5

#	ARTICLE	IF	CITATIONS
55	Wilms' tumor gene 1 immunotherapy in pelvic gynecological malignancies. Expert Review of Clinical Immunology, 2014, 10, 705-711.	3.0	4
56	Circulating Transcripts and Biomarkers in Uterine Tumors: Is There a Predictive Role?. Current Oncology Reports, 2020, 22, 12.	4.0	4
57	Effect of Particle Carriers for Intraperitoneal Drug Delivery on the Course of Ovarian Cancer and Its Immune Microenvironment in a Mouse Model. Pharmaceutics, 2022, 14, 687.	4.5	4
58	Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer. Npj Genomic Medicine, 2022, 7, 30.	3.8	4
59	Wilms's™ tumour gene 1 (WT1) positivity in endothelial cells surrounding epithelial uterine tumours. Histopathology, 2009, 54, 384-387.	2.9	3
60	Intraperitoneal injection of cultured mesothelial cells decrease CO2 pneumoperitoneum-enhanced adhesions in a laparoscopic mouse model. Gynecological Surgery, 2011, 8, 409-414.	0.9	1
61	Orientation of Preclinical Research in Ovarian Cancer. International Journal of Gynecological Cancer, 2017, 27, 1579-1586.	2.5	0